2. Amyotrophic lateral sclerosis Clinical trials / Disease details

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05281484 (ClinicalTrials.gov)	August 31, 2022	7/3/2022	Intermediate Expanded Access Protocol (EAP) CNMAu8.EAP02	A Second Intermediate Expanded Access Protocol for Amyotrophic Lateral Sclerosis With CNM-Au8	Amyotrophic Lateral Sclerosis	Drug: CNM-Au8	Clene Nanomedicine	NULL	Available	18 Years	N/A	All			United States
2	NCT05299658 (ClinicalTrials.gov)	November 13, 2021	8/3/2022	An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS	An Open-Label Extension for the Phase 2, Randomised, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS	Amyotrophic Lateral Sclerosis	Drug: CNMAu8	Clene Nanomedicine	NULL	Active, not recruiting	30 Years	80 Years	All	40	Phase 2	Australia
3	NCT03843710 (ClinicalTrials.gov)	April 30, 2021	14/2/2019	31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)	A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: Gold Nanocrystals	Clene Nanomedicine	University of Texas Southwestern Medical Center	Not yet recruiting	35 Years	75 Years	All	24	Phase 2	United States
4	NCT04297683 (ClinicalTrials.gov)	July 14, 2020	3/3/2020	HEALEY ALS Platform Trial - Master Protocol	HEALEY ALS Platform Trial	Amyotrophic Lateral Sclerosis	Drug: Zilucoplan;Drug: Verdiperstat;Drug: CNM-Au8;Drug: Pridopidine;Drug: SLS -005 Trehalose	Merit E. Cudkowicz, MD	Massachusetts General Hospital	Recruiting	18 Years	N/A	All	800	Phase 2/Phase 3	United States
5	NCT04098406 (ClinicalTrials.gov)	December 19, 2019	19/9/2019	Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS.	Amyotrophic Lateral Sclerosis	Drug: CNM-Au8;Drug: Placebo	Clene Nanomedicine	Clene Australia Pty Ltd	Completed	30 Years	80 Years	All	45	Phase 2	Australia
6	NCT04081714 (ClinicalTrials.gov)	August 31, 2019	5/9/2019	Intermediate Expanded Access Protocol for ALS	An Intermediate Expanded Access Protocol for Amyotrophic Lateral Sclerosis With CNM-Au8	Amyotrophic Lateral Sclerosis	Drug: CNM-Au8	Clene Nanomedicine	Massachusetts General Hospital	Available	18 Years	N/A	All			United States